• Elastic Dual-Network Hydrogel Microspheres for IVDD Therapy

  2026-05-07

  This study reports a multifunctional hydrogel microsphere system engineered for targeted delivery of miRNA therapeutics in intervertebral disc degeneration (IVDD). By integrating EGCG-based metal-phenolic networks, the platform achieves sustained miRNA release, inflammation modulation, and apoptosis inhibition, with promising implications for restoring disc function in degenerative conditions.

• Dual-Action Kinase Inhibitors Promote p38α MAPK Dephosphoryl

  2026-05-07

  The referenced study uncovers how certain kinase inhibitors not only block p38α MAP kinase activity but also accelerate its dephosphorylation by stabilizing a conformation accessible to phosphatases. These findings provide a mechanistic basis for developing more specific and potent p38α MAPK inhibitors, with implications for inflammation and autoimmune research.

• Targeting sEH: Translational Advances with BPN-19186 in Bone

  2026-05-06

  Explore how (S)-1-(3-fluoro-4-(trifluoromethoxy)phenyl)-3-(1-(2-methylbutanoyl)piperidin-4-yl)urea (BPN-19186) empowers translational researchers to dissect liver-bone crosstalk, redox balance, and osteoclastogenesis. Drawing on breakthrough evidence that positions hepatic soluble epoxide hydrolase (sEH) as a central regulator of bone homeostasis via Nrf2 signaling suppression, this article connects mechanistic insight with actionable experimental strategies and protocol guidance. Learn how APExBIO's high-purity small molecule inhibitor translates these findings to the bench, outpacing standard compound pages by offering strategic, workflow-ready perspectives.

• Doxorubicin Hydrochloride in Dual-Loaded Liposome Research

  2026-05-06

  Explore the advanced role of Doxorubicin hydrochloride in dual-loaded liposome systems for cancer chemotherapy research. This article delivers new insights into encapsulation efficiency, practical assay setups, and translational applications—distinct from standard mechanistic or toxicity reviews.

• Merimepodib (VX-497): Protocols for Antiviral & Immunology R

  2026-05-05

  Merimepodib (VX-497) stands out as a selective, orally bioavailable IMPDH inhibitor for targeted studies in antiviral, cancer, and immunosuppression research. This guide delivers evidence-based workflows, troubleshooting strategies, and insights from recent breakthroughs to maximize research outcomes using APExBIO's trusted reagent.

• SHC-1 Inhibition Elevates CFTR Surface Abundance in Epitheli

  2026-05-05

  This study elucidates how SHC-1 adaptor protein inhibition can modulate the plasma membrane abundance of the CFTR chloride channel in diverse epithelial cell models. The findings refine our understanding of CFTR trafficking and highlight cell-type specificity, with implications for cystic fibrosis, COPD, and secretory disease research.

• Cy3-UTP: Precision RNA Labeling for Imaging and Interaction

  2026-05-04

  Cy3-UTP empowers researchers to generate highly photostable, fluorescent RNA for advanced imaging and quantitative interaction assays. Its robust incorporation during in vitro transcription and compatibility with high-sensitivity detection platforms make it an essential reagent for dissecting RNA dynamics at single-nucleotide resolution.

• Oligo (dT) 25 Beads: Technical Guide for mRNA Isolation

  2026-05-04

  Oligo (dT) 25 Beads enable researchers to isolate polyadenylated eukaryotic mRNA with high specificity and efficiency, directly from total RNA or cell/tissue lysates. These superparamagnetic beads are suited for workflows requiring intact mRNA for cDNA synthesis or advanced molecular assays, but should not be used for non-polyA RNAs or prokaryotic samples.

• CD44-Driven Metabolic Rewiring in IDH-Mutant Leukemia: Thera

  2026-05-03

  This article dissects new evidence that CD44 is essential for sustaining NADPH-dependent 2-hydroxyglutarate (2-HG) production in IDH-mutant acute myeloid leukemia (AML), revealing a novel metabolic vulnerability. The findings suggest that combined targeting of mutant IDH1 and CD44-mediated pathways could inform more effective therapeutic strategies.

• Oleanolic Acid and iNOS Induction: Dual-Loaded Liposome Work

  2026-05-02

  Harnessing oleanolic acid’s potent inducible nitric oxide synthase induction, researchers can achieve high-efficiency dual-loaded liposome encapsulation—crucial for antiviral and immune pathway studies. This guide translates recent encapsulation efficiency breakthroughs and troubleshooting strategies into actionable steps, optimized for APExBIO’s high-purity oleanolic acid.

• Cy3 NHS Ester (Non-Sulfonated): Technical Guide for Fluoresc

  2026-05-01

  Cy3 NHS ester (non-sulfonated) provides sensitive and reproducible labeling of amino-containing biomolecules, enabling robust detection in biomedical imaging and quantitative assays. It is best suited for workflows where organic co-solvents are compatible, but is not recommended for applications requiring strictly aqueous labeling conditions or extended storage of dye solutions.

• Resibufogenin Blocks NLRP3 Inflammasome to Counter Atheroscl

  2026-05-01

  This study reveals resibufogenin as a potent inhibitor of the NLRP3 inflammasome, significantly mitigating atherosclerosis in ApoE-/- mice. The findings highlight both a novel molecular target and a promising therapeutic candidate for inflammatory cardiovascular diseases.

• Acid Sphingomyelinase Drives Diabetic Cardiomyopathy via Mit

  2026-04-30

  Wei et al. reveal that acid sphingomyelinase (ASMase) promotes diabetic cardiomyopathy by disrupting mitochondrial calcium homeostasis through enhanced formation of mitochondria-associated ER membranes (MAMs) and MICU1 activation. Targeting the ASMase–MICU1 axis emerges as a potential therapeutic strategy, as loss of ASMase restores mitochondrial function and reduces cardiomyocyte apoptosis in diabetic models.

• Zosuquidar (LY335979) for Overcoming Multidrug Resistance in

  2026-04-30

  Zosuquidar (LY335979) 3HCl, supplied by APExBIO, is redefining the reversal of multidrug resistance in cancer by targeting the P-glycoprotein efflux pump. Explore workflow enhancements, robust troubleshooting, and translational impact, with actionable assay guidance rooted in recent pharmacokinetic and transporter research.

• Applied Workflows with BCA Protein Assay Kit for Protein Qua

  2026-04-29

  The BCA Protein Assay Kit empowers researchers with sensitive, reproducible protein quantification even in complex matrices like brain endothelial lysates. This article details optimized workflows and troubleshooting strategies that unlock robust data for mechanistic and translational studies, including recent advances in BBB pathophysiology.

8464 records 13/565 page Previous Next First page 上5页 1112131415 下5页 Last page